After the UK-based parent of GSK Pharma announced an open offer proposing to buy nearly 25% of the firm at a price of Rs 3,100 per share – a nearly 26% premium to the stock‘s Friday closing price, CNBC-TV18 spoke with Ranjit Kapadia, Pharma Analyst, Centrum Broking, to get his view.
first published: Dec 16, 2013 10:57 am
A collection of the most-viewed Moneycontrol videos.
India’s top private bankers reveal where the next 100-baggers will emerge
Will Nifty Extend Rally To Day 4 After 52-Week High? RIL, Banks In Focus | Opening Bell Live
The Lawyer Renting in one of Mumbai’s most green societies | The Tenant
Live: Nifty extends gain for the third day, up nearly 2% this week | Closing Bell | 4K
